Oncotelic Therapeutics (OTLC) Research & Development (2010 - 2026)
Oncotelic Therapeutics (OTLC) reported Research & Development of $345.00 for Q2 2026, up 16.2% from $297.00 a year earlier.
Powered by 
Analysis
Oncotelic Therapeutics (OTLC) Research & Development (2010 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Oncotelic Therapeutics' Research & Development came in at $1,419, up 7.0% year-over-year; for FY2025, it was $4,357.
- Research & Development has a five-year compound annual growth rate of -74.8% (FY2020 to FY2025).
- By year, Research & Development came in at $61,143 in FY2023 (-91.9%), $756,910 in FY2022 (-79.3%) and $3.66 million in FY2021 (-15.0%).
- The Q2 2026 figure ranks as the highest quarterly Research & Development since Q3 2024.
- Year over year, Research & Development gained in two of the last four quarters, with an average decline of 25.5%.
- The high point for year-over-year Research & Development in five years was Q2 2025 (growth of 17.9%); the low point was Q3 2022 (a decline of 99.7%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,109.83 Bn | 1,078.42 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 610.61 Bn | 529.14 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 500.66 Bn | 473.77 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 354.64 Bn | 309.02 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 291.14 Bn | 255.13 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 254.18 Bn | 227.87 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 229.46 Bn | 184.86 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 190.33 Bn | 164.53 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 167.92 Bn | 114.57 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Oncotelic Therapeutics | 8.28 Mn | 7.42 Mn | - | 345.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 345.00 |
| Jun 30, 2025 | 297.00 |
| Mar 31, 2025 | 297.00 |
| Sep 30, 2024 | 480.00 |
| Jun 30, 2024 | 252.00 |
| Mar 31, 2024 | 480.00 |
| Dec 31, 2023 | 10,995.00 |
| Sep 30, 2023 | 21,221.00 |
| Jun 30, 2023 | -36,989.00 |
| Mar 31, 2023 | 65,916.00 |
| Dec 31, 2022 | 66,205.00 |
| Sep 30, 2022 | 1,700.00 |
| Jun 30, 2022 | 108,707.00 |
| Mar 31, 2022 | 580,297.00 |
| Dec 31, 2021 | 523,204.00 |
| Sep 30, 2021 | 621,927.00 |
| Jun 30, 2021 | 956,814.00 |
| Mar 31, 2021 | 1.56 Mn |
| Dec 31, 2020 | 2.57 Mn |
| Sep 30, 2020 | 936,196.00 |
API Access
Oncotelic Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=OTLC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "OTLC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=OTLC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();